According to this study, the global Immuno-oncology Therapy market size will reach US$ 1763 million by 2031.

Immuno-oncology therapy is a type of cancer treatment that harnesses the bodys immune system to target and destroy cancer cells. It includes therapies such as immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies.

The market for immuno-oncology therapy is driven by the growing interest in personalized and targeted cancer treatments and the need for innovative therapies with fewer side effects. The markets growth is also influenced by the approval of new immuno-oncology drugs and ongoing research in cancer immunotherapy.

LPI (LP Information) newest research report, the Immuno-oncology Therapy Industry Forecast looks at past sales and reviews total world Immuno-oncology Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Immuno-oncology Therapy sales for 2025 through 2031. With Immuno-oncology Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immuno-oncology Therapy industry.

This Insight Report provides a comprehensive analysis of the global Immuno-oncology Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immuno-oncology Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Immuno-oncology Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immuno-oncology Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immuno-oncology Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Immuno-oncology Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Monoclonal Antibodies
    Immune Checkpoint Inhibitors
    Immune System Modulators
    Cancer Vaccines

Segmentation by Application:

    Hospitals
    Ambulatory Surgical Center
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Amgen
    AstraZeneca
    Bristol-Myers Squibb
    Eli-Lilly
    Roche
    GlaxoSmithKline
    Janssen Biotech
    Merck
    Novartis
    Pfizer
    Sanofi
    Spectrum Pharmaceuticals
    Takeda
    BioNTech SE
    Allogene Therapeutics
    IMAB-I-Mab Biopharma Co., Ltd.
    Arcus Biosciences
    Gritstone Oncology
    Autolus Therapeutics
    Rubius Therapeutics